PMID- 26517296
OWN - NLM
STAT- MEDLINE
DCOM- 20180409
LR  - 20180629
IS  - 1552-4957 (Electronic)
IS  - 1552-4949 (Linking)
VI  - 92
IP  - 4
DP  - 2017 Jul
TI  - Immunophenotypic and cytogenetic findings of B-lymphoblastic leukemia/lymphoma 
      associated with combined IGH/BCL2 and MYC rearrangement.
PG  - 310-314
LID - 10.1002/cyto.b.21334 [doi]
AB  - BACKGROUND: B-lymphoblastic leukemias (B-LBL) with combined IGH/BCL2 and MYC 
      rearrangement are rare and their clinical, cytogenetic and immunophenotypic 
      features are not well characterized. Here, we describe a case of a 61-year-old 
      woman with B-LBL associated with these cytogenetic alterations and present a 
      review of the literature of this disease. METHODS: Four-color flow cytometry (FC) 
      was performed on a BD FACSCanto II flow cytometer. Data were analyzed with BD 
      FACSDiva software. Cytogenetic, fluorescence in situ hybridization (FISH), and 
      molecular studies were performed by conventional methods. A review of the 
      literature was performed by a PubMed-assisted search. RESULTS: Including our 
      case, eight B-LBLs associated with a documented "double-hit" karyotype (IGH/BCL2 
      and 8q24/MYC rearrangement) were identified in the literature (male/female 2/6, 
      age 15-65). Three occurred de-novo, and five had a history of a CD10+ B-cell 
      lymphoma. The typical immunophenotype was CD10, CD19, TdT positive, and negative 
      for CD34 and surface immunoglobulin (Ig), established either by FC or 
      immunohistochemistry. Seven cases were CD20-, and one case was CD20+. 
      Translocation partners of MYC varied, and included IGH, lambda light chain, and 
      an unknown gene on chromosome 9. Prognosis was poor with median survival of five 
      months. CONCLUSIONS: Patients with B-LBL associated with a combined IGH/BCL2 and 
      MYC rearrangement often have a history of a mature B-cell lymphoma. The 
      immunophenotype of these cases is different from that of mature "double-hit" 
      lymphomas; FC is essential to differentiate the B-LBL cases from the leukemic 
      phase of mature B-cell lymphomas. (c) 2015 International Clinical Cytometry 
      Society.
CI  - (c) 2015 International Clinical Cytometry Society.
FAU - Kelemen, Katalin
AU  - Kelemen K
AD  - Department of Laboratory Medicine and Pathology, Mayo Clinic Hospital, Phoenix, 
      Arizona.
FAU - Holden, Jaclyn
AU  - Holden J
AD  - Department of Laboratory Medicine and Pathology, Mayo Clinic Hospital, Phoenix, 
      Arizona.
FAU - Johnson, Laura J
AU  - Johnson LJ
AD  - Department of Laboratory Medicine and Pathology, Mayo Clinic Hospital, Phoenix, 
      Arizona.
FAU - Davion, Simone
AU  - Davion S
AD  - Department of Pathology, the Billings Clinic, Billings, Montana.
FAU - Robetorye, Ryan S
AU  - Robetorye RS
AD  - Department of Laboratory Medicine and Pathology, Mayo Clinic Hospital, Phoenix, 
      Arizona.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Review
DEP - 20160205
PL  - United States
TA  - Cytometry B Clin Cytom
JT  - Cytometry. Part B, Clinical cytometry
JID - 101235690
RN  - 0 (Antigens, CD)
RN  - 0 (BCL2 protein, human)
RN  - 0 (Immunoglobulin Heavy Chains)
RN  - 0 (MYC protein, human)
RN  - 0 (Oncogene Proteins, Fusion)
RN  - 0 (Proto-Oncogene Proteins c-bcl-2)
RN  - 0 (Proto-Oncogene Proteins c-myc)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Antigens, CD/genetics/immunology
MH  - Female
MH  - Flow Cytometry/methods
MH  - Humans
MH  - Immunoglobulin Heavy Chains/*genetics/metabolism
MH  - Immunophenotyping
MH  - Karyotyping
MH  - Middle Aged
MH  - Oncogene Proteins, Fusion/*genetics/immunology
MH  - Precursor B-Cell Lymphoblastic 
      Leukemia-Lymphoma/*diagnosis/*genetics/mortality/pathology
MH  - Prognosis
MH  - Proto-Oncogene Proteins c-bcl-2/*genetics/immunology
MH  - Proto-Oncogene Proteins c-myc/*genetics/immunology
MH  - Survival Analysis
MH  - Translocation, Genetic
OTO - NOTNLM
OT  - B-lymphoblastic leukemia/lymphoma
OT  - IGH/BCL2 translocation
OT  - MYC rearrangement
OT  - immunophenotype
EDAT- 2015/10/31 06:00
MHDA- 2018/04/10 06:00
CRDT- 2015/10/31 06:00
PHST- 2015/04/13 00:00 [received]
PHST- 2015/10/19 00:00 [revised]
PHST- 2015/10/28 00:00 [accepted]
PHST- 2015/10/31 06:00 [pubmed]
PHST- 2018/04/10 06:00 [medline]
PHST- 2015/10/31 06:00 [entrez]
AID - 10.1002/cyto.b.21334 [doi]
PST - ppublish
SO  - Cytometry B Clin Cytom. 2017 Jul;92(4):310-314. doi: 10.1002/cyto.b.21334. Epub 
      2016 Feb 5.